Archives
-
Monomethyl auristatin E (MMAE) Assays
2026-09-03
A scenario-based guide to using Monomethyl auristatin E (MMAE), SKU A3631, in cell viability, proliferation, and cytotoxicity workflows. It covers mechanism, solvent compatibility, dose design, data interpretation, and practical criteria for selecting a reliable reagent.
-
(S)-(+)-Dimethindene maleate Workflow
2026-09-02
This article provides a practical workflow for evaluating (S)-(+)-Dimethindene maleate as an M2 muscarinic receptor antagonist while accounting for its additional histamine H1 activity. It is intended for controlled pharmacological research, not diagnostic, therapeutic, or medical use, and should be interpreted within the limits of dossier-based evidence.
-
Chemerin–cNTS Signaling Raises Blood Pressure
2026-09-02
This 2024 study identifies a chemerin-CMKLR1–NADPH oxidase–superoxide pathway in the caudal nucleus tractus solitarius that increases sympathetic activity, blood pressure, and heart rate. Its pharmacological circuit analysis further indicates that the downstream cardiovascular response depends on NMDA-sensitive paraventricular nucleus signaling rather than AMPA/kainate transmission under the tested conditions.
-
Tankyrase Inhibitors and Hippo Signaling in HCC
2026-09-01
Jia et al. show that the tankyrase inhibitors G007-LK and XAV-939 restrain hepatocellular carcinoma cell growth while suppressing YAP activity through stabilization of AMOTL1 and AMOTL2. The study expands the mechanistic view of tankyrase inhibition beyond Wnt signaling and provides a practical framework for connecting colony formation, Hippo-pathway readouts, and combination treatment experiments.
-
LY2109761: A Causal Map of TGF-β Signaling
2026-09-01
LY2109761 is a TGF-β receptor type I and II dual inhibitor that helps researchers separate receptor-proximal signaling from downstream oxidative stress and phenotype changes. This article presents a causal, assay-centered framework for interpreting Smad2/3, migration, fibrosis, cancer, and radiation-response data.
-
CRTC–CREB Senses Proteotoxic Stress in Drosophila
2026-08-31
The reference study identifies CRTC–CREB as a transcriptional sensor that links proteasome inhibition to ROS/JNK signaling and adaptive stress responses in Drosophila. Its findings connect proteostasis regulation with protein-aggregation disease models and provide a mechanistic framework for interpreting MLN2238-induced CREB activation.
-
CHAP Model for Bleeding Risk in Extended VTE
2026-08-31
This prospective multinational cohort study evaluated bleeding prediction during extended anticoagulation after unprovoked or weakly provoked venous thromboembolism. It found that modified ACCP, VTE-BLEED, and HAS-BLED scores identified patients at higher risk, while the simpler CHAP model offered comparable discrimination by retaining continuous measures of creatinine, hemoglobin, and age.
-
Midecamycin: From Ribosome Mechanism to Translation
2026-08-30
Midecamycin is more than a conventional macrolide antibiotic research reagent. Its defined interaction with bacterial 23S rRNA, selective activity against Gram-positive organisms, susceptibility to glycosylation-based attenuation, and documented erythromycin cross-resistance create a practical framework for translational study design. This article connects mechanism, assay strategy, resistance interpretation, and biosynthetic engineering to help researchers use Midecamycin as an antibiotic research compound with clearer decision points from discovery through validation.
-
Tankyrase Inhibitors and Hippo Signaling in HCC
2026-08-29
The reference study shows that XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth through a mechanism involving AMOTL1/2 stabilization, YAP reduction, and Hippo-pathway transcriptional inhibition. Its main contribution is to extend tankyrase biology beyond Wnt regulation and provide a rationale for combining tankyrase inhibition with MEK or AKT pathway blockade.
-
Breast Cancer Dependence on MCL-1: Study Insights
2026-08-28
The reference study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic activity, rather than because of an apoptosis-independent tumor-support function. By combining genetic deletion, selective pharmacological inhibition, immune-competent tumor models, and BAX/BAK epistasis, the work connects MCL-1 targeting to mitochondrial apoptosis and provides a framework for interpreting stemness-related findings.
-
Tivozanib (AV-951) In Vitro Workflow Guide
2026-08-28
Tivozanib (AV-951) combines picomolar VEGFR-2 potency with a comparatively selective kinase profile, making it useful for dissecting angiogenic signaling and treatment response in cancer models. This workflow emphasizes formulation control, time-resolved viability and death measurements, and combination testing rather than relying on a single endpoint.
-
Iptacopan (LNP023): Reading Complement Signals
2026-08-27
Iptacopan (LNP023) offers a precise way to interrogate alternative-pathway amplification through reversible factor B inhibition. This article connects convertase biology with assay selection, disease-model interpretation, and translational complement research.
-
Imidazoline Antagonists and β-Cell K+ Channels
2026-08-27
The reference study showed that alinidine, antazoline, phentolamine, and Tolazoline increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than solely by blocking α2-adrenoceptors. Its combined use of 86Rb efflux, whole-cell patch clamp, and pharmacological rescue experiments provides a useful framework for interpreting imidazoline effects in islet function research.
-
Iptacopan Monotherapy in PNH: Evidence and Methods
2026-08-26
The reference study provides early clinical proof of concept that oral, single-agent factor B inhibition with Iptacopan (LNP023) can rapidly reduce hemolysis in treatment-naive patients with paroxysmal nocturnal hemoglobinuria. Its two-cohort design links proximal alternative pathway blockade with improvements in lactate dehydrogenase, hemoglobin, and transfusion status, while also defining important limitations for later controlled trials.
-
S-Adenosylhomocysteine in Translational Research
2026-08-26
S-Adenosylhomocysteine (SAH) is more than a methylation-cycle by-product: it is a mechanistic lever for testing how methylation potential, metabolic state, and cell fate interact. This article connects SAH biology with radiation-associated neural differentiation while defining practical boundaries between evidence, hypothesis, and translational opportunity.